False positives a concern in new colon cancer test

WASHINGTON — The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests that use DNA from a patient’s stool to detect dangerous tumors and growths.

FDA scientists have questions about the accuracy and the potential real-world impact of the kits from Epigenomics and Exact Sciences, according to briefing documents posted online Monday. The agency released its reviews of the tests ahead of a two-day meeting that starts Wednesday.

Read article

Share